Chromocell Therapeutics Co. (NYSE:CHRO – Get Free Report) shares fell 4.7% on Thursday . The company traded as low as $1.60 and last traded at $1.63. 8,474 shares changed hands during trading, a decline of 99% from the average session volume of 1,564,620 shares. The stock had previously closed at $1.71.
Chromocell Therapeutics Price Performance
The firm’s 50-day simple moving average is $1.39 and its 200 day simple moving average is $0.96.
Chromocell Therapeutics Company Profile
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain.
Further Reading
- Five stocks we like better than Chromocell Therapeutics
- How to Invest in Insurance Companies: A Guide
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- DuPont’s Electronics Spinoff: The Start of Something Big
- Financial Services Stocks Investing
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Chromocell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromocell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
